Show simple item record

dc.contributor.authorSchijven, Jack
dc.contributor.authorBrizee, Sabrina
dc.contributor.authorTeunis, Peter
dc.contributor.authorde Vos, Clazien
dc.contributor.authorEblé, Phaedra
dc.contributor.authorRutjes, Saskia
dc.date.accessioned2019-02-03T18:29:49Z
dc.date.available2019-02-03T18:29:49Z
dc.date.issued2018-11-05
dc.identifier.issn1539-6924
dc.identifier.pmid30395685
dc.identifier.doi10.1111/risa.13227
dc.identifier.urihttp://hdl.handle.net/10029/622403
dc.description.abstractSome viruses cause tumor regression and can be used to treat cancer patients; these viruses are called oncolytic viruses. To assess whether oncolytic viruses from animal origin excreted by patients pose a health risk for livestock, a quantitative risk assessment (QRA) was performed to estimate the risk for the Dutch pig industry after environmental release of Seneca Valley virus (SVV). The QRA assumed SVV excretion in stool by one cancer patient on Day 1 in the Netherlands, discharge of SVV with treated wastewater into the river Meuse, downstream intake of river water for drinking water production, and consumption of this drinking water by pigs. Dose-response curves for SVV infection and clinical disease in pigs were constructed from experimental data. In the worst scenario (four logen_US
dc.language.isoenen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.subjectDose responseen_US
dc.subjectSeneca Valley virusen_US
dc.subjectoncolytic virusen_US
dc.subjectpigsen_US
dc.subjectquantitative risk assessmenten_US
dc.titleQuantitative Assessment of the Health Risk for Livestock When Animal Viruses Are Applied in Human Oncolytic Therapy: A Case Study for Seneca Valley Virus.en_US
dc.typeArticleen_US
dc.identifier.journalRisk Anal 2019; 39(5):982-91en_US
dc.source.journaltitleRisk analysis : an official publication of the Society for Risk Analysis


This item appears in the following Collection(s)

Show simple item record